How the Cathelicidin Peptide LL-37 Drives Rosacea — and How Colchicine Blocks It
Colchicine reduced rosacea symptoms in mice by blocking the interaction between the antimicrobial peptide LL-37 and TLR2 on neutrophils, reducing inflammation and redness.
Quick Facts
What This Study Found
LL-37 cathelicidin directly binds to TLR2 on neutrophils to drive rosacea inflammation, and colchicine disrupts this binding, reducing inflammatory markers, NET formation, and rosacea-like symptoms in mice.
Key Numbers
Colchicine reduced redness scores, inflammatory biomarkers, and neutrophil infiltration in the rosacea mouse model.
How They Did This
LL-37-induced rosacea mouse model treated with colchicine. Assessed skin redness scores, inflammatory biomarkers via RT-PCR, neutrophil infiltration via immunohistochemistry, NET formation, and TLR2-LL-37 binding via coimmunoprecipitation. Validated with bioinformatics analysis.
Why This Research Matters
This study reveals the specific molecular mechanism by which the peptide LL-37 causes rosacea — by binding TLR2 on neutrophils. Understanding this peptide-receptor interaction could lead to more targeted treatments for the millions of people living with rosacea.
The Bigger Picture
LL-37 is a key antimicrobial peptide in human skin defense, but its overexpression is a known driver of rosacea. This study maps out the specific inflammatory pathway — LL-37 → TLR2 → neutrophil activation → NETs — providing a roadmap for targeted interventions. Colchicine, already approved for gout and other inflammatory conditions, could potentially be repurposed for rosacea.
What This Study Doesn't Tell Us
Mouse rosacea model induced by external LL-37 injection may not fully replicate human disease, where LL-37 overproduction is endogenous. Colchicine has gastrointestinal and other side effects that need clinical evaluation in rosacea patients. No human trial data.
Questions This Raises
- ?Would colchicine be effective and tolerable in human rosacea patients, given its known side effect profile?
- ?Could drugs that specifically block the LL-37-TLR2 interaction be developed as targeted rosacea treatments?
- ?Does this TLR2 pathway also explain the flare patterns seen in different rosacea subtypes?
Trust & Context
- Key Stat:
- LL-37 binds TLR2 Discovery that the cathelicidin peptide directly activates neutrophil inflammation through TLR2, explaining a key mechanism behind rosacea
- Evidence Grade:
- Preliminary evidence: well-designed mouse model study with clear mechanistic findings, but no human clinical data yet.
- Study Age:
- Published in 2024. Provides new mechanistic insights into cathelicidin-driven rosacea.
- Original Title:
- Colchicine Alleviates Rosacea by Inhibiting Neutrophil Inflammation Activated by the TLR2 Pathway.
- Published In:
- Inflammation, 47(3), 1002-1014 (2024)
- Authors:
- Yuan, Xin, Sheng, Liang, Shi, Guang, Jiang, Leiwei, Lian, Chengxiang
- Database ID:
- RPEP-09619
Evidence Hierarchy
Frequently Asked Questions
What role does the peptide LL-37 play in rosacea?
LL-37 (cathelicidin) is an antimicrobial peptide that normally helps protect skin from infections. In rosacea, it is overproduced and triggers excessive inflammation by binding to TLR2 receptors on neutrophils, causing redness, swelling, and pustules.
Could colchicine become a rosacea treatment?
This mouse study suggests it could work by blocking the LL-37-TLR2 inflammatory pathway. Colchicine is already prescribed for gout and other inflammatory conditions, which could speed up its evaluation for rosacea. However, human trials are needed first.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09619APA
Yuan, Xin; Sheng, Liang; Shi, Guang; Jiang, Leiwei; Lian, Chengxiang. (2024). Colchicine Alleviates Rosacea by Inhibiting Neutrophil Inflammation Activated by the TLR2 Pathway.. Inflammation, 47(3), 1002-1014. https://doi.org/10.1007/s10753-023-01956-6
MLA
Yuan, Xin, et al. "Colchicine Alleviates Rosacea by Inhibiting Neutrophil Inflammation Activated by the TLR2 Pathway.." Inflammation, 2024. https://doi.org/10.1007/s10753-023-01956-6
RethinkPeptides
RethinkPeptides Research Database. "Colchicine Alleviates Rosacea by Inhibiting Neutrophil Infla..." RPEP-09619. Retrieved from https://rethinkpeptides.com/research/yuan-2024-colchicine-alleviates-rosacea-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.